Element Biosciences Secures $175 Million in Series E Funding

Element Biosciences, a company focused on developing innovative genomic and multiomic technologies, has announced a significant milestone in its growth journey. On June 9, 2026, the company revealed it had raised $175 million in a Series E funding round. This round was led by Samsung Electronics, marking a continued partnership and commitment to advancing life sciences and precision medicine.

Leadership and Vision

Element Biosciences was co-founded by Matthew Kellinger, with Molly He serving as the CEO. Under their leadership, the company has been expanding its reach and capabilities in the genomic and multiomic sectors. CEO Molly He emphasized the importance of this funding, stating: "This investment allows us to further our mission of providing comprehensive biological insights to researchers and clinicians globally."

Strategic Use of Funds

The newly acquired funds will be directed towards several key initiatives:

  • Commercialization and Global Expansion: The capital will support the commercialization of Element's growing ecosystem of technologies and aid in its global expansion efforts.
  • Product Portfolio Development: The funding will drive the adoption of Element's existing product portfolio, including the AVITI sequencing platform, and support the launch of new products such as the VITARI high-throughput benchtop system, AVITI Dx, and tissue profiling capabilities on AVITI24.
  • Research and Development: Continued development of future technologies is planned, aimed at providing broader biological insights for researchers.

Platform and Market Reach

Element Biosciences is known for its open and interoperable platform architecture, which allows for collaboration with scientific, pharmaceutical, and technology partners. Since launching its AVITI platform in 2022, the company has expanded its offerings beyond sequencing to include genomic, transcriptomic, protein, spatial, and cellular analysis technologies. Element now serves a diverse customer base across more than 40 countries, including academic institutions, pharmaceutical companies, biotechnology firms, and clinical research organizations.

Samsung's Continued Investment

Samsung Electronics, as the lead investor, continues to show confidence in Element Biosciences' vision and progress. TM Roh, President and Head of the Device eXperience Division at Samsung Electronics, commented on the investment: "Samsung believes in the broad adoption of sequencing as a foundational pillar in precision medicine, and we are extremely confident in Element’s progress, vision, and team."

This funding round positions Element Biosciences to further its impact in the field of precision medicine and personalized diagnostics, enhancing its capability to support groundbreaking research and clinical applications.